Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation.

Pecci A, Malara A, Badalucco S, Bozzi V, Torti M, Balduini CL, Balduini A.

Thromb Haemost. 2009 Jul;102(1):90-6. doi: 10.1160/TH09-01-0068.

PMID:
19572073
2.

Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD.

Freedman BI, Hicks PJ, Bostrom MA, Comeau ME, Divers J, Bleyer AJ, Kopp JB, Winkler CA, Nelson GW, Langefeld CD, Bowden DW.

Nephrol Dial Transplant. 2009 Nov;24(11):3366-71. doi: 10.1093/ndt/gfp316. Epub 2009 Jun 30.

3.

Genome-wide linkage analysis of serum creatinine in three isolated European populations.

Pattaro C, Aulchenko YS, Isaacs A, Vitart V, Hayward C, Franklin CS, Polasek O, Kolcic I, Biloglav Z, Campbell S, Hastie N, Lauc G, Meitinger T, Oostra BA, Gyllensten U, Wilson JF, Pichler I, Hicks AA, Campbell H, Wright AF, Rudan I, van Duijn CM, Riegler P, Marroni F, Pramstaller PP; EUROSPAN Consortium..

Kidney Int. 2009 Aug;76(3):297-306. doi: 10.1038/ki.2009.135. Epub 2009 Apr 22.

4.

Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.

Freedman BI, Hicks PJ, Bostrom MA, Cunningham ME, Liu Y, Divers J, Kopp JB, Winkler CA, Nelson GW, Langefeld CD, Bowden DW.

Kidney Int. 2009 Apr;75(7):736-45. doi: 10.1038/ki.2008.701. Epub 2009 Jan 28.

5.

MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.

Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA.

Nat Genet. 2008 Oct;40(10):1175-84. doi: 10.1038/ng.226. Epub 2008 Sep 14.

6.

MYH9 is associated with nondiabetic end-stage renal disease in African Americans.

Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS; Family Investigation of Nephropathy and Diabetes Research Group..

Nat Genet. 2008 Oct;40(10):1185-92. doi: 10.1038/ng.232. Epub 2008 Sep 14.

7.

A new multipoint method for genome-wide association studies by imputation of genotypes.

Marchini J, Howie B, Myers S, McVean G, Donnelly P.

Nat Genet. 2007 Jul;39(7):906-13. Epub 2007 Jun 17.

PMID:
17572673
8.

C1q nephropathy: a variant of focal segmental glomerulosclerosis.

Markowitz GS, Schwimmer JA, Stokes MB, Nasr S, Seigle RL, Valeri AM, D'Agati VD.

Kidney Int. 2003 Oct;64(4):1232-40.

9.

Collapsing glomerulopathy.

Schwimmer JA, Markowitz GS, Valeri A, Appel GB.

Semin Nephrol. 2003 Mar;23(2):209-18. Review.

PMID:
12704581
10.

Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes.

Arrondel C, Vodovar N, Knebelmann B, Grünfeld JP, Gubler MC, Antignac C, Heidet L.

J Am Soc Nephrol. 2002 Jan;13(1):65-74.

11.

Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study.

Valeri A, Barisoni L, Appel GB, Seigle R, D'Agati V.

Kidney Int. 1996 Nov;50(5):1734-46.

12.

C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome.

Jennette JC, Hipp CG.

Am J Kidney Dis. 1985 Aug;6(2):103-10.

PMID:
3875286
13.

C1q nephropathy: a pediatric clinicopathologic study.

Iskandar SS, Browning MC, Lorentz WB.

Am J Kidney Dis. 1991 Oct;18(4):459-65.

PMID:
1928065

Supplemental Content

Support Center